Maurie Markman

Syed A. Abutalib

Kenneth C. Anderson

James O. Armitage

CANCER CONSULT New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes: Up-to-date clinically relevant information on the very latest topics such as molecular techniques, targeted therapies, immunotherapy, BMT, CAR T-cell therapy and translational cancer research Sections on ALL, AML, myeloid neoplasms, CLL, Hodgkin’s and Non-Hodgkin’s lymphomas, amongst other topics Streamlined, engaging content to make finding information easier and less time consuming for the reader Concise and practical expert perspectives that reference key studies References to the latest NCCN, ESMO, ASH, ASTCT, EBMT and other national guidelines With its powerful focus on pragmatic clinical diagnostic, therapeutic and prognostic approaches, Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition will help keep hematology, oncology and cellular therapy practitioners up-to-date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base. It also offers clinicians, trainees, and fellows an excellent opportunity to enhance their preparation for the ABIM, hematology and oncology fellowship and recertification exams.

Neoplastic Hematology & Cellular Therapy

Cancer Consult: Expertise in Clinical Practice, Volume 2

Christopher D. Hillyer

Leslie E. Silberstein

Paul M. Ness

John D. Roback

Ever since the discovery of blood types early in the last century, transfusion medicine has evolved at a breakneck pace. This second edition of Blood Banking and Transfusion Medicine is exactly what you need to keep up. It combines scientific foundations with today's most practical approaches to the specialty. From blood collection and storage to testing and transfusing blood components, and finally cellular engineering, you'll find coverage here that's second to none. New advances in molecular genetics and the scientific mechanisms underlying the field are also covered, with an emphasis on the clinical implications for treatment. Whether you're new to the field or an old pro, this book belongs in your reference library. - Integrates scientific foundations with clinical relevance to more clearly explain the science and its application to clinical practice. - Highlights advances in the use of blood products and new methods of disease treatment while providing the most up-to-date information on these fast-moving topics - Discusses current clinical controversies, providing an arena for the discussion of sensitive topics. - Covers the constantly changing approaches to stem cell transplantation and brings you the latest information on this controversial topic.

Basic Principles and Practice

Blood Banking and Transfusion Medicine

Robert Marcus

Stephen A. Schey

Kwee L. Yong

Myeloma is the second-most common hematologic cancer, accounting for approximately 1 percent of all cancers and 2 percent of all deaths from cancer. In recent years there have been major and significant advances in the diagnosis, imaging, molecular pathogenesis, and therapy of myeloma. This book describes these advances in a single, practical volume, placing them in the context of daily clinical practice. Different myeloma subtypes are discussed in individual chapters, integrating etiology, pathogenesis, molecular pathology, histology, and therapy in a single place for each condition. The book begins by discussing epidemiology, imaging techniques, pathogenesis, and other general considerations. Conditions covered in detail include multiple myeloma, POEMS syndrome, Castleman's syndrome, Waldenstrom's macroglobulinemia, amyloidosis and MGUS. Featuring color illustrations, and written and edited by leading authorities in the field, Myeloma provides readers with the information they need to diagnose and manage these complex disorders.

Pathology, Diagnosis, and Treatment

Myeloma

Nikhil C. Munshi

Despite the advances in conventional, novel agent and high dose chemotherapy multiple myeloma (MM) remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in MM focusing on the development of molecularly-based combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. Two major advances are making this goal possible. First, recent advances in genomics and proteomics in MM have allowed for increased understanding of disease pathogenesis, identified novel therapeutic targets, allowed for molecular classification, and provided the scientific rationale for combining targeted therapies to increase tumor cell cytotoxicity and abrogate drug resistance. Second, there is now an increased understanding of how adhesion of MM cells in bone marrow (BM) further impacts gene expression in MM cells, as well as in BM stromal cells (BMSCs). As a result of these advances in oncogenomics on the one hand and increased understanding of the role of the BM in the pathogenesis of MM on the other, a new treatment paradigm targeting the tumor cell and its BM microenvironment to overcome drug resistance and improve patient outcome has now been developed. Thalidomide, lenalidomide, and Bortezomib are three agents which target the tumor cell in its microenvironment in both laboratory and animal models and which have rapidly translated from the bench to the bedside. Ongoing efforts are using oncogenomics and cell signaling studies to identify next generation of therapies in MM on the one hand, and to inform the design of combination trials on the other. This new paradigm for overcoming drug resistance and improving patient outcome in MM has great promise not only to change the natural history of MM, but also to serve as a model for targeted therapeutics directed to improve outcome of patients with MM.

Volume 2: Translational and Clinical Research

Advances in Biology and Therapy of Multiple Myeloma

Razelle Kurzrock

Apostolia-Maria Tsimberidou

Translational medicine has opened the gateway to the era of personalized medicine. No longer a one-size-fits-all approach, the treatment of cancer is now based on an understanding of underlying biologic mechanisms and is increasingly being tailored to the molecular specificity of a tumor. Translational Oncology: Targeted Therapy in Translational Cancer Research provides a comprehensive overview of the pertinent molecular discoveries in the cancer field and explains the clinical ramifications and utility of these on targeted cancer therapies. Beginning with a chapter introducing the “Bench to Bedside and Back” paradigm, an overview is presented of the exponential growth in the field of translational medicine, including historical perspectives and recent progress. Following the introduction, subsequent chapters review the progress of targeted therapy within three major categories: hematological malignancies, solid tumors, and hereditary cancers. Each of these categories comprises a single a chapter with subsections that discuss specific cancer types. Following this is a chapter on targeted and functional imaging that reviews progress in the different modalities of anatomical and molecular imaging used to complement targeted therapy. The next chapter discusses the need to combine individual agents with existing therapies or in novel combinations in order to overcome drug resistance. Following this is a chapter presenting the challenges in drug development and the selection of targets for cancer therapeutics. The final chapter offers perspectives on personalized medicine and presents future challenges in the investigation of optimal combinations and the identification of biomarkers that can provide both predictive and prognostic information for tailoring targeted therapies to individual patients.

Targeted Therapy in Translational Cancer Research

Ever since the discovery of blood types early in the last century, transfusion medicine has evolved at a breakneck pace. This second edition of Blood Banking and Transfusion Medicine is exactly what you need to keep up. It combines scientific foundations with today's most practical approaches to the specialty. From blood collection and storage to testing and transfusing blood components, and finally cellular engineering, you'll find coverage here that's second to none. New advances in molecular genetics and the scientific mechanisms underlying the field are also covered, with an emphasis on the clinical implications for treatment. Whether you're new to the field or an old pro, this book belongs in your reference library. Integrates scientific foundations with clinical relevance to more clearly explain the science and its application to clinical practice. Highlights advances in the use of blood products and new methods of disease treatment while providing the most up-to-date information on these fast-moving topics Discusses current clinical controversies, providing an arena for the discussion of sensitive topics. Covers the constantly changing approaches to stem cell transplantation and brings you the latest information on this controversial topic.

Basic Principles & Practice

Volume 1: Basic Science

Kenneth C. Anderson

Books

Your next favorite book is out there